Lutropin alfa Other names: Luteinizing hormone beta subunit Human Urinary luteinizing hormone (LH) Lutropin beta chain precursor

Therapeutic indications

Lutropin alfa is indicated for:

Stimulation of follicular development in severe Luteinising Hormone (LH) deficiency

Population group: women, only adults (18 - 65 years old)

Lutropin alfa in association with a Follicle Stimulating Hormone (FSH) preparation is recommended for the stimulation of follicular development in adult women with severe Luteinising Hormone (LH) and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level <1.2 IU/l.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lutropin alfa is contraindicated in the following cases:

Tumours of the hypothalamus and pituitary gland

at least one of
Tumor of hypothalamus
Neoplasm of pituitary gland

Ovarian enlargement, ovarian cyst

at least one of
Ovarian enlargement
Ovarian cyst

Gynaecological haemorrhages of unknown origin

Hematometra

Ovarian carcinoma

Malignant epithelial tumor of ovary

Uterine carcinoma

Carcinoma of uterus

Mammary carcinoma

CA - Carcinoma of breast

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: LUVERIS Powder and solvent for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈